FH-006 for Injection

Phase 2

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JNGHF)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Feb '27

JNGHFPhase 2

FH-006 for Injection Phase 2 Est. Readout

FH-006 for Injection• Malignant Solid Tumor150

Feb 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Malignant Solid Tumor

View Full Landscape

Drug Information

Target Indication

Malignant Solid Tumor

Clinical Trial

NCT07136142

Last updated: 9/5/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

JNGHF

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Biotechnology•North America•NASDAQ

Related Pipeline

X0002 SprayPhase 3

KNEE OSTEOARTHRITIS

JSKN003Phase 3

Advanced Solid Tumor

ApatinibPhase 3

Carcinoma, Hepatocellular

HRS-4357 injectionPhase 3

PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer

Irinotecan liposome、5-Fluorouracil、LeucovorinPhase 3

Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts